New Agents in Melanoma: Nivolumab, MK-3475, Pidilizumab
Dr. Atkins offers his perspective on the “race” between the top two anti-PD1 drugs (Merck’s MK-3475 and Bristol-Myers Squibb’s nivolumab), and weighs in on where a new agent, pidilizumab, fits into the picture.
Michael B. Atkins, MD, deputy director of the Georgetown-Lombardi Comprehensive Cancer Center, offers his perspective on the “race” between the top two anti-PD1 drugs (Merck’s MK-3475 and Bristol-Myers Squibb’s nivolumab) and insights as to which anti-PD1 agents are also showing the greatest promise in non-melanoma cancers. Dr. Atkins presented on phase II results of the new anti-PD1 drug pidilizumab at the 2014 ASCO Annual Meeting and weighs in on where this new agent fits into the picture.
Recent Videos
![A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F6b7c9a3270c71a70749ba86000cfc78a29d74309-2988x1702.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.")
Related Content
